Key result
Dronedarone decreased stroke risk by 34%, and dabigatran b.i.d. showed significant stroke reductions compared with adjusted-dose warfarin in patients with atrial fibrillation.
Why the study?
Do novel antiarrhythmic and antithrombotic drugs reduce stroke risk in patients with atrial fibrillation?
Do novel antiarrhythmic and antithrombotic drugs reduce stroke risk in patients with atrial fibrillation?
Novel antithrombotic and antiarrhythmic agents like dabigatran and dronedarone may enhance stroke risk management in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support stroke prevention strategies with dronedarone or dabigatran in AF; leaves open need for confirmatory prospective trials.
BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with increased cardiovascular mortality and morbidity, including stroke. RESULTS: Rate or rhythm control and prevention of thromboembolism with oral anticoagulants are the main management objectives for patients with AF. Until recently, rhythm control studies did not show prevention of cardiovascular complications. However, dronedarone, a novel antiarrhythmic drug, has been shown to decrease stroke risk by 34% (p = 0.027). In addition, the Randomized Evaluation of Long-Term Anticoagulant Therapy trial showed significant stroke reductions with the anticoagulant dabigatran 150 mg b.i.d. compared with adjusted-dose warfarin (the results for dabigatran 110 mg b.i.d. were similar to warfarin). CONCLUSIONS: Novel antithrombotic agents and antiarrhythmic agents with cardiovascular prophylactic properties may enhance the management of stroke risk in patients with AF.
No takes yet. Share an insight, caveat, or question.
Röther et al. (2010) conducted a review in Atrial fibrillation. Novel antiarrhythmic and antithrombotic drugs (dronedarone, dabigatran) vs. adjusted-dose warfarin was evaluated on stroke (34% decrease, p=0.027). Dronedarone decreased stroke risk by 34%, and dabigatran b.i.d. showed significant stroke reductions compared with adjusted-dose warfarin in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: